Skip to main content

Table 2 Genotype and haplotype frequencies of VEGF 3′-UTR polymorphisms

From: Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans

 

Without MetS

With MetS

Genotype/Haplotype

Control (n = 305)

CC (n = 166)

RC (n = 113)

Control (n = 95)

CC (n = 98)

RC (n = 73)

VEGF 1451CC

209 (68.5)

108 (65.1)

64 (56.6)

65 (68.4)

72 (73.5)

45 (61.6)

VEGF 1451CT

81 (26.6)

50 (30.1)

43 (38.1)

29 (30.5)

23 (23.5)

27 (37.0)

VEGF 1451TT

15 (4.9)

8 (4.8)

6 (5.3)

1 (1.1)

3 (3.1)

1 (1.4)

HWE-p

0.059

0.483

0.724

0.251

0.493

0.167

VEGF 1612GG

213 (69.8)

127 (76.5)

87 (77.0)

67 (70.5)

68 (69.4)

54 (74.0)

VEGF 1612GA

83 (27.2)

36 (21.7)

21 (18.6)

27 (28.4)

29 (29.6)

18 (24.7)

VEGF 1612AA

9 (3.0)

3 (1.8)

5 (4.4)

1 (1.1)

1 (1.0)

1 (1.4)

HWE-p

0.791

0.809

0.022

0.336

0.271

0.714

VEGF 1725GG

278 (91.1)

147 (88.6)

96 (85.0)

81 (85.3)

79 (80.6)

61 (83.6)

VEGF 1725GA

27 (8.9)

19 (11.4)

17 (15.0)

14 (14.7)

19 (19.4)

12 (16.4)

VEGF 1725AA

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

HWE-p

0.419

0.434

0.387

0.438

0.288

0.444

VEGF 1451C/1612G/1725G

398 (65.2)

221 (65.6)

140 (61.9)

130 (68.4)

134 (68.4)

96 (65.8)

VEGF 1451T/1612G/1725G

111 (18.2)

66 (19.9)

55 (24.3)

31 (16.3)

29 (14.8)

29 (19.9)

VEGF 1451C/1612A/1725G

74 (12.1)

26 (7.8)

14 (6.2)

15 (7.9)

14 (7.1)

9 (6.2)

VEGF 1451C/1612A/1725A

27 (4.4)

16 (4.8)

17 (7.5)

14 (7.4)

17 (8.7)

11 (7.5)

VEGF 1451C/1612G/1725A

0 (0.0)

3 (0.9)

0 (0.0)

0 (0.0)

2 (1.0)

1 (0.7)

  1. Vascular endothelial growth factor (VEGF), Colon cancer (CC), Rectal cancer (RC), Metabolic syndrome (MetS), Hardy-Weinberg equilibrium (HWE).